WO2022101267A3 - Compositions for delivery of an adsorbent - Google Patents

Compositions for delivery of an adsorbent Download PDF

Info

Publication number
WO2022101267A3
WO2022101267A3 PCT/EP2021/081240 EP2021081240W WO2022101267A3 WO 2022101267 A3 WO2022101267 A3 WO 2022101267A3 EP 2021081240 W EP2021081240 W EP 2021081240W WO 2022101267 A3 WO2022101267 A3 WO 2022101267A3
Authority
WO
WIPO (PCT)
Prior art keywords
adsorbent
compositions
delivery
site
subject
Prior art date
Application number
PCT/EP2021/081240
Other languages
French (fr)
Other versions
WO2022101267A2 (en
Inventor
Thibaut Richard
Friederike MAYENFELS
Julian HAAS
Ansgar BÖGERSHAUSEN
Original Assignee
Da Volterra
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Da Volterra filed Critical Da Volterra
Publication of WO2022101267A2 publication Critical patent/WO2022101267A2/en
Publication of WO2022101267A3 publication Critical patent/WO2022101267A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/44—Elemental carbon, e.g. charcoal, carbon black
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention relates to compositions and solid dosage forms for the site-specific delivery of an adsorbent into the gastrointestinal tract of a subject.
PCT/EP2021/081240 2020-11-12 2021-11-10 Compositions for delivery of an adsorbent WO2022101267A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20306372 2020-11-12
EP20306372.2 2020-11-12

Publications (2)

Publication Number Publication Date
WO2022101267A2 WO2022101267A2 (en) 2022-05-19
WO2022101267A3 true WO2022101267A3 (en) 2022-07-07

Family

ID=73698740

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2021/081240 WO2022101267A2 (en) 2020-11-12 2021-11-10 Compositions for delivery of an adsorbent

Country Status (1)

Country Link
WO (1) WO2022101267A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632451B2 (en) * 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
WO2006122835A1 (en) * 2005-05-18 2006-11-23 Da Volterra Colonic delivery of adsorbents
WO2010143207A1 (en) * 2009-06-11 2010-12-16 Rubicon Research Private Limited Taste-masked oral formulations of influenza antivirals

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8048413B2 (en) 2006-05-17 2011-11-01 Helene Huguet Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules
ES2586135T3 (en) 2010-02-23 2016-10-11 Da Volterra Formulations for the oral supply of adsorbents in the intestine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632451B2 (en) * 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
WO2006122835A1 (en) * 2005-05-18 2006-11-23 Da Volterra Colonic delivery of adsorbents
WO2010143207A1 (en) * 2009-06-11 2010-12-16 Rubicon Research Private Limited Taste-masked oral formulations of influenza antivirals

Also Published As

Publication number Publication date
WO2022101267A2 (en) 2022-05-19

Similar Documents

Publication Publication Date Title
EP4233978A3 (en) Oral delivery of active drug substances
MX340822B (en) Formulations for oral delivery of adsorbents in the gut.
GB2458403A (en) Corticosteroid compositions
MX2021010868A (en) Bacterium of the christensenellaceae family for the prevention and/or treatment of chronic inflammatory diseases and/or inflammatory gastrointestinal diseases and/or cancers.
MX2011001782A (en) Pharmaceutical composition and administrations thereof.
EA031157B9 (en) Orally administered corticosteroid composition
HK1129581A1 (en)
MX2020009857A (en) Il-2 conjugates.
SA517390550B1 (en) Orodispersible Dosage Unit Containing an Estetrol Component
MY174797A (en) Anti-inflammatory compositions
MA34286B1 (en) PHARMACEUTICAL COMPOSITIONS AND METHODS OF MAKING THEM
PL3793534T3 (en) An oral tablet for delivery of active ingredients to the gastrointestinal tract
MX2013000642A (en) Pharmaceutical compositions comprising r (+) budesonide and one or more bronchodilators.
HK1104795A1 (en) Dry formulations of aripiprazole
MX2021013341A (en) Solid forms of a glyt1 inhibitor.
WO2011128627A8 (en) Oral veterinary pharmaceutical and nutraceutical compositions
MX2024005839A (en) Lysine acetyltransferase 6a (kat6a) inhibitors and uses thereof.
EP3908251A4 (en) Pharmaceutical delivery compositions and uses thereof
EP3840735A4 (en) Capsule device for delivery of active agent to gastrointestinal tract
EP4135699A4 (en) Pharmaceutical compositions
WO2017093810A3 (en) Composition for intraoral delivery of biologically active peptides and proteins
WO2022101267A3 (en) Compositions for delivery of an adsorbent
MX2024009106A (en) Pharmaceutical composition containing acetominophen and ibuprofen.
PH12020551368A1 (en) Composition for enhancing cognitive function, composition for remedying anxiety symptoms, and composition for suppressing cerebral atrophy
EP4257136A3 (en) Preparation of a solid pharmaceutical composition comprising rivaroxaban and production thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21805973

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21805973

Country of ref document: EP

Kind code of ref document: A2